<div id="readability-page-1"><div> By Paul Vieira <pre></pre> OTTAWA--Canada said Friday it intends to accelerate drug approvals in the country by relying on work done by foreign pharmaceutical regulators. Canada's health department said in a notice that this marks an effort to address industry concerns about the time it takes to get a new drug to market, and meet growing domestic demand for essential pharmaceutical products. The ministry said it proposes to lean on work done earlier by foreign regulators without compromising safety. The proposed changes, as outlined in the government's official newspaper, Canada Gazette, would create a more attractive environment for businesses, officials said. Relying on international collaboration would allow Canada's health department &#34;to refocus resources . . . narrow the gap in product availability, and contribute to earlier availability of products on the Canadian market,&#34; according to the government notice. Canada is seeking input from drug makers and healthcare organizations for a 70-day period, until Feb. 28, before publishing final regulations. A list of approved foreign drug regulators wasn't published at this time. This initiative is part of Prime Minister Mark Carney's effort to reduce and eliminate regulatory barriers within the federal public sector. Carney's administration is also looking to shed as many as 40,000 workers from the federal public-sector payrolls, or a reduction of about 10% from current levels. <pre></pre> Write to Paul Vieira at paul.vieira@wsj.com <pre></pre> (END) Dow Jones Newswires December 19, 2025 15:36 ET (20:36 GMT)Copyright (c) 2025 Dow Jones &amp; Company, Inc.</div></div>

加拿大计划通过利用外国监管机构的工作来加快药物审批，以应对行业担忧和国内需求。该倡议旨在创造一个有利于商业的环境，并改善产品的可用性。药品制造商和医疗保健组织的意见将在 2 月 28 日之前征集。这是总理马克·卡尼努力减少监管障碍并削减 10% 联邦公共部门职位的一部分

加拿大将依靠外国监管机构来加速药品审批流程